Have previous osteoarthritis (OA) of the knee treatments failed to provide adequate relief?

Adults living with osteoarthritis (OA) of the knee could qualify for a research study evaluating a potential new investigational medication. To qualify, you must be at least 18 years old and have been diagnosed with OA of the knee.

​

STUDY DETAILS
Osteoarthritis of the knee is estimated to affect over 90 million people in the US. 
 
Knee replacement surgery is effective in the treatment of severe osteoarthritis (OA), however, it's often the last resort in favor of therapies that effectively manage symptoms or those that slow, stop, or even reverse joint damage.
 

Organogenesis is researching the effectiveness of an amniotic suspension allograft (ASA) for the treatment of inflammatory disorders, including OA of the knee. Placental products, including amniotic tissues, have been studied for a number of different conditions, possess anti-inflammatory properties, and have demonstrated a favorable safety profile. In this study, patients will receive an injection of ASA or placebo (normal saline) and be followed for up to 52 weeks (12 months).

​

You may qualify for the study if you:

• Are at least 18 years old

• Have been diagnosed with OA of the knee 

• Have failed to respond to at least 2 osteoarthritis therapies in the past 12 months (based on study requirements) 

​

Qualified participants receive:

• Study-related care at no cost

• Study-related medical exams at no cost

• Compensation up to $800 for time and travel

​